Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24012402 | 0.86 | CNR2 (0.32) | FOLH1CHRM2CHRM4CHRM1 | |
| SCHEMBL22375471 | 0.83 | FOLH1 (0.32) | FOLH1MMP3MMP9 | |
| SCHEMBL22375760 | 0.83 | ADRB2 (0.31) | FOLH1 | |
| SCHEMBL13539964 | 0.83 | CHRM2 (0.47) | FOLH1CHRM2CHRM4CHRM1 | |
| SCHEMBL24012449 | 0.82 | FOLH1 (0.30) | FOLH1 | |
| SCHEMBL23080176 | 0.81 | ACHE (0.38) | FOLH1 | |
| SCHEMBL24295447 | 0.79 | CTSL (0.34) | CHRM2CHRM4CHRM1 | |
| SCHEMBL14679231 | 0.76 | MMP3 (0.47) | MMP3MMP9 | |
| SCHEMBL14374994 | 0.76 | MMP3 (0.42) | MMP3MMP9 | |
| SCHEMBL13539965 | 0.76 | NOS1 (0.40) | CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | GLP1R, GIPR, GRPR | FOLH1 149/4885MMP3 2656/4885MMP9 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.